Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06534060 · ClinicalTrials.gov registry record · Phase 2
MB-105 in Patients With CD5 Positive T-cell Lymphoma
A Phase 2 study of Lymphoma, T-Cell, sponsored by March Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 12
- Study locations
NCT06534060 is a Phase 2 study of Lymphoma, T-Cell that is actively recruiting participants, run by March Biosciences. The registered enrollment target is 46 participants, below the 121-participant average among 9 other Lymphoma, T-Cell trials with a reported enrollment target (62% lower). The trial reports 12 study locations across 11 states.
The verdict
NCT06534060, a Phase 2 study of Lymphoma, T-Cell, is actively recruiting participants, sponsored by March Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Conditions Studied
Interventions
- BIOLOGICAL Genetic: MB-105
Study Locations (12)
Texas
- Baylor College of Medicine - Houston
- MD Anderson Cancer Center - Houston
California
- University of San Diego (UCSD)-Moores Cancer Center - San Diego
Colorado
- SCRI - Colorado Blood Cancer Institute (CBCI) - Denver
Florida
- Moffitt Cancer Center Magnolia Campus - Tampa
Iowa
- University of Iowa - Iowa City
Massachusetts
- Massachusetts General Hospital - Boston
Nebraska
- University of Nebraska - Omaha
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2025-02-15 |
| Est. Completion | 2029-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06534060
The ClinicalTrials.gov registry entry for NCT06534060 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 121-participant average among 9 other Lymphoma, T-Cell trials with a reported enrollment target (62% lower). The listed sponsor is March Biosciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma, T-Cell appearing as the primary indexed condition, and to 1 intervention - of which Genetic: MB-105 is the first listed.
NCT06534060 reports 12 study locations spanning 11 distinct geographic areas - top geographies include Texas, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06534060 about?
NCT06534060 is a clinical study titled "MB-105 in Patients With CD5 Positive T-cell Lymphoma". This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
What is the current status of trial NCT06534060?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2025-02-15. Estimated completion is 2029-12.
What conditions does trial NCT06534060 study?
This clinical trial studies the following conditions: Lymphoma, T-Cell.
What interventions are being tested in trial NCT06534060?
The interventions under investigation include: Genetic: MB-105 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06534060?
This trial is sponsored by March Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06534060 being conducted?
This trial has 12 study locations across California, Colorado, Florida, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, T-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
COMPLETED · Phase 2
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
RECRUITING · Phase 1
-
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.